Juvenescence Ltd Amends AgeX Therapeutics Stake

TL;DR

Juvenescence Ltd filed another update on their AgeX Therapeutics stake. Keep an eye on this one.

AI Summary

Juvenescence Ltd, through its filing on March 26, 2024, amended its Schedule 13D regarding AgeX Therapeutics, Inc. This amendment, the 34th, indicates a change in the beneficial ownership of AgeX Therapeutics, Inc. common stock. The filing does not specify dollar amounts or exact share changes but signifies an ongoing disclosure of significant ownership.

Why It Matters

This filing indicates a potential shift in control or influence over AgeX Therapeutics, Inc. by a significant shareholder, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often signal changes in significant ownership, which can lead to increased volatility and strategic shifts for the company.

Key Players & Entities

• Juvenescence Ltd (company) — Filing entity
• AgeX Therapeutics, Inc. (company) — Subject company
• David Gill (person) — Person authorized to receive notices

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $900,000 — Issuer each in the principal amount of $900,000. SIGNATURES After reasonable inquiry

Filing Documents

• tm249774d1_sc13da.htm (SC 13D/A) — 42KB
• 0001104659-24-039008.txt ( ) — 44KB

of the Original Statement is hereby amended and restated in

Item 5 of the Original Statement is hereby amended and restated in its entirety to read as follows: (a) The Reporting Persons beneficially owns an aggregate of 2,667,458 shares of Common Stock, representing (i) 1,889,323 shares of Common Stock held directly by JuvVentures (UK) Limited, (ii) 8,773 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the New Facility (as defined below), (iii) 294,482 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the A&R Secured Note (as defined below) and (iv) 474,879 shares of Common Stock that may be issued upon conversion of outstanding amounts under the A&R Secured Note at the closing price of the Common Stock on March 20, 2024 . This aggregate amount represents approximately 81.4% of the Issuer’s outstanding common stock, based upon 2,500,664 shares outstanding as of March 14, 2024, as reported on the Issuer’s Annual Report filed on Form 10-K on March 25, 2024 and giving effect to the exercise of the Warrants and conversion of amounts outstanding under the A&R Secured Note. (b) The information in Items 7 through 10 of each cover page is incorporated by reference into this Item 5(b). (c) Except for the information set forth in Item 6, which is incorporated by reference into this Item 5(c), the Reporting Persons have effected no transactions relating to the Common Stock during the past 60 days. (d) - (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

of the Original Statement is hereby supplemented as follows

Item 6 of the Original Statement is hereby supplemented as follows: On March 20, 2024, the Reporting Person funded additional advances to the Issuer each in the principal amount of $900,000.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct. Date: March 25, 2024 JUVENESCENCE LIMITED By: /s/ Gregory H. Bailey Name: Gregory H. Bailey Title: Executive Chairman Date: March 25, 2024 JuvVentures (UK) Limited By: /s/ David Gill Name: David Gill Title: Director

View Full Filing

View this SC 13D/A filing on SEC EDGAR